Discovery of Orally Efficacious Phosphoinositide 3-Kinase δ Inhibitors with Improved Metabolic Stability-Reference-Cited by-同舟云学术

Discovery of Orally Efficacious Phosphoinositide 3-Kinase δ Inhibitors with Improved Metabolic Stability

Published:2016-10-03 Issue:19 Volume:59 Page:9228-9242
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Patel Leena¹,Chandrasekhar Jayaraman¹,Evarts Jerry¹,Forseth Kristen¹,Haran Aaron C.¹,Ip Carmen¹,Kashishian Adam¹,Kim Musong¹,Koditek David¹,Koppenol Sandy¹,Lad Latesh¹,Lepist Eve-Irene¹,McGrath Mary E.¹,Perreault Stephane¹,Puri Kamal D.¹,Villaseñor Armando G.¹,Somoza John R.¹,Steiner Bart H.¹,Therrien Joseph¹,Treiberg Jennifer¹,Phillips Gary¹

Affiliation:

1. Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6b01169

Reference48 articles.

1. Targeting PI3K signalling in cancer: opportunities, challenges and limitations

2. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

3. Signal Transduction Inhibitor Therapy for Lymphoma